References
- Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD [updated 2018] Available from: http://www.goldcopd.orgAccessed November 15, 2017
- FrithPAThompsonPJRatnavadivelRGlisten Study GroupGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study–a randomised controlled trialThorax201570651952725841237
- SilerTMKerwinESingletaryKBrooksJChurchAEfficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studiesCOPD201613111026451734
- SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
- LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
- VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
- YuAPGuérinAPonce de LeonDTherapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ201114448649621679019
- YuAPGuérinAPonce de LeonDClinical and economic outcomes of multiple versus single long-acting inhalers in COPDRespir Med2011105121861187121807487
- Lechuga-BallesterosDNogaBVehringRCummingsRHDwivediSKNovel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthmaFuture Med Chem20113131703171821942257
- VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
- DotyASchroederJVangKDrug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliabilityAAPS Pharm Sci Tech2018192837844
- CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
- MillerMRHankinsonJBrusascoVATS/ERS Task ForceStandardisation of spirometryEur Respir J200526231933816055882
- DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
- RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
- SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
- TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
- FergusonGTTashkinDPSkärbyTEffect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) studyRespir Med2017132314129229103
- ReisnerCFabbriLMKerwinEMA randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseRespir Res2017181828061907
- SharafkhanehAMattewalASAbrahamVMDronavalliGHananiaNABudesonide/formoterol combination in COPD: a US perspectiveInt J Chron Obstruct Pulmon Dis2010535736621037960
- BattistiWPWagerEBaltzerLInternational Society for Medical Publication ProfessionalsGood publication practice for communicating company-sponsored medical research: GPP3Ann Intern Med2015163646146426259067